Travere Therapeutics (TVTX) is back in focus after new long term data from its Phase 3 DUPLEX Study open label extension showed sustained, clinically meaningful proteinuria reductions in focal segmental glomerulosclerosis patients on FILSPARI.

The latest DUPLEX data and recent licensing moves have arrived after a powerful run, with Travere’s share price up 58.07% over 90 days and a 1 year total shareholder return close to 3x, although short term share price momentum has cooled in recent sessions.

If kidney disease and biotech therapies are on your radar, this is a good moment to scan a wider field of healthcare innovators through our screener of 39 healthcare AI stocks.

After a share price that has nearly tripled over 12 months and trades about 20% below the average analyst target, the key question now is whether Travere is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 14.5% Undervalued

Travere’s most followed valuation narrative places fair value at $53.57 per share, versus a last close of $45.81. This frames the current discount and the debate that goes with it.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market if approved. This will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

Analysts are baking in rapid revenue expansion, sharply higher margins, and a richer future earnings multiple. Curious how those moving parts add up to that fair value.

Result: Fair Value of $53.57 (UNDERVALUED)

However, this story can shift quickly if FILSPARI faces tougher competition than analysts expect or if regulatory requirements around REMS and pricing become more stringent.

Another View on Value

Multiples tell a more cautious story. Travere trades on a P/S of 7.9x, above the fair ratio of 7x that the market could move toward, yet below the US Biotechs average of 10.9x and peer average of 12.7x. Is that a margin of safety or a warning sign?

Next Steps

With mixed signals on value and sentiment, it makes sense to move quickly, review the numbers yourself, and weigh both the upside and the risks; start by checking the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop at one stock, you risk missing out on other opportunities that could fit your goals even better, so broaden your search before making your next move.

• Spot potential value plays early by scanning our collection of 49 high quality undervalued stocks that pair quality with attractive pricing.
• Prioritise resilience by focusing on companies in the 63 resilient stocks with low risk scores that score well on stability and business risk checks.
• Hunt for future standouts by using the screener containing 22 high quality undiscovered gems to surface quality stocks that many investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.